Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045300 | 0.93 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL19043991 | 0.83 | — | — | |
| SCHEMBL12166551 | 0.79 | SHBG (0.30) | L3MBTL1 | |
| SCHEMBL21431988 | 0.74 | MAPT (0.32) | — | |
| SCHEMBL17895049 | 0.74 | MAPT (0.32) | — | |
| SCHEMBL27983118 | 0.71 | — | — | |
| SCHEMBL4988233 | 0.70 | — | — | |
| SCHEMBL12536749 | 0.70 | — | — | |
| SCHEMBL30589484 | 0.70 | — | — | |
| SCHEMBL23196708 | 0.70 | TRPA1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119391494-A | Essence light stabilizer and liquid detergent composition applied by same | 广州立白科技集团有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-9717712-B2 | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717712-B2 | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160166547-A1 | Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus | BRISTOL MYERS SQUIBB CO (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166547-A1 | Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus | HAVCR2, HCCS, MAVS | L3MBTL1 3269/4885GAA 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.